Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

Avraham Frisch, Chezi Ganzel, Yishai Ofran, Baher Krayem, Vladimir Vainstein, Arnon Haran, Boaz Nachmias

Blood (2023) 142 (Supplement 1): 4212.

https://doi.org/10.1182/blood-2023-179194

Published: 2023

Journal Articles

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial

Blood (2023) 142 (Supplement 1): 594.

https://doi.org/10.1182/blood-2023-189734

Published: 2023

Journal Articles

AML Drug Tolerant Persister (DTP) Cells Survive Chemotherapy By Transiently Altering Cellular Lipidomics to Increase Plasma Membrane Rigidity, but Also Increases Sensitivity to Immune Cell Killing

Yael Morgenstern, JongBok Lee, Yoosu Na, William Gwynne, Rose Hurren, Li Ma, Marcela Gronda, Chaitra Sarathy, Arvind Mer, Andrea Arruda, Avraham Frisch, Tsila Zuckerman, Yishai Ofran, Mark D. Minden, Li Zhang, Catherine O'Brien, J. Rafael Montenegro-Burke, Aaron D. Schimmer

Blood (2023) 142 (Supplement 1): 2806.

https://doi.org/10.1182/blood-2023-178995

Published: 2023

Journal Articles

Daunorubicin/Cytarabine Liposome +/- Gemtuzumab Ozogamicin for Adult Patients with Newly Diagnosed, Low-Intermediate Risk, FLT3-Wild Type, AML: A Pilot Study

Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Ellen Broide, Emmanuel Benayoun, Jacob M. Rowe, Yishai Ofran

Blood (2023) 142 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2023-185052

Published: 2023

Journal Articles

Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report

Irina Amitai, Ilana Hellmann, Maya Koren-Michowitz, Tsila Zuckerman, Ariel Aviv, Anatoly Nemets, Itai Levi, Yishai Ofran, Moshe Mittelman, Drorit Grizim Merkel

Blood (2022) 140 (Supplement 1): 12349–12350.

https://doi.org/10.1182/blood-2022-166542

Published: 2022

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

Blood (2022) 140 (Supplement 1): 6162–6164.

https://doi.org/10.1182/blood-2022-163020

Published: 2022

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

Ofir Wolach, Itai Levi, David Lavie, Jonathan Canaani, Sigal Tavor, Ilana Hellmann, Tamar Tadmor, Tsila Zuckerman, Galia Stemer, Jenia Berelovich, Keren Ofek, Neta Frankel, Moshe Grunspan, Yishai Ofran, Yakir Moshe

Blood (2021) 138 (Supplement 1): 1246.

https://doi.org/10.1182/blood-2021-147245

Published: 2021

Journal Articles

In Patients with Acute Myeloid Leukemia, Hidac Administered on Days 1, 2 and 3 of Consolidation Course Is As Efficacious As Hidac Given on Days 1, 3 and 5, but Is Better Tolerated

Baher Krayem, Avraham Frisch, Nurit Horesh, Ronit Leiba, Tsila Zuckerman, Yishai Ofran

Blood (2021) 138 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2021-152532

Published: 2021

Journal Articles

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study

Yishai Ofran, Zhuoxin Sun, Jacob M. Rowe, David F. Claxton, Martin S. Tallman, Daniel A. Arber, Ari Melnick, Ross L. Levine, Elisabeth Paietta, John E. Godwin, Hillard M Lazarus, Selina M. Luger, James M. Foran, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 413.

https://doi.org/10.1182/blood-2021-149356

Published: 2021

Journal Articles

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Brian A Jonas, MD PhD, Courtney D. Dinardo, MDMSc, Nicola Fracchiolla, Alexander Pristupa, MD, Kenichi Ishizawa, MD PhD, Jie Jin, MD PhD, Marina Konopleva, MD PhD, Yishai Ofran, Pau Montesinos, MD PhD, Tibor Kovacsovics, MD, Jun-Ho Jang, MD, Hagop M. Kantarjian, MD, Wan-Jen Hong, MD, Yinghui Duan, PhD, William Ainsworth, Jalaja Potluri, MD, Michael Werner, Anders Erik Svensson, MD, Keith W. Pratz, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-134850

Published: 2020

Journal Articles

RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-143352

Published: 2020

Journal Articles

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Ofir Wolach, MD, Itai Levi, MD, Jonathan Canaani, MD, Tamar Tadmor, MD, Sigal Tavor, MD, Ilana Hellmann, MD, Tsila Zuckerman, MD, David Lavie, MD, Galia Stemer, MD, Raanan Cohen, MD, Ran Afik, PhD, Keren Ofek, PhD, Hilla Banayan, BSc MBA, Inna Kan, PhD, Moshe Grunspan, PhD, Yishai Ofran, MD, Yakir Moshe, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139923

Published: 2020

Journal Articles

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-133912

Published: 2020

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Yishai Ofran, MD, Ronit Leiba, Dina Rosenberg, Israel Henig, MD, Dana Yehudai-Ofir, MD, Nuhad Haddad, MD, Riva Fineman, MD, Avraham Frisch, MD, Doaa Okasha, MD, Yariv Carasso, MD, Tsila Zuckerman, MD, Nurit Horesh, MD

Blood (2019) 134 (Supplement_1): 2603.

https://doi.org/10.1182/blood-2019-126553

Published: 2019

Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD

Blood (2019) 134 (Supplement_1): 2662.

https://doi.org/10.1182/blood-2019-125966

Published: 2019

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

NARROW

Outcome of Risk- and Response-Adapted Post-Remission Therapy in Patients with NPM1 AML Treated Intensively

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial

AML Drug Tolerant Persister (DTP) Cells Survive Chemotherapy By Transiently Altering Cellular Lipidomics to Increase Plasma Membrane Rigidity, but Also Increases Sensitivity to Immune Cell Killing

Daunorubicin/Cytarabine Liposome +/- Gemtuzumab Ozogamicin for Adult Patients with Newly Diagnosed, Low-Intermediate Risk, FLT3-Wild Type, AML: A Pilot Study

Yoga As Possible Non-Medical Intervention to Improve Quality of Life of Patients with Myelodysplastic Syndromes - a Feasibility Report

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice - a Prospective Analysis from the Revive Study

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study

In Patients with Acute Myeloid Leukemia, Hidac Administered on Days 1, 2 and 3 of Consolidation Course Is As Efficacious As Hidac Given on Days 1, 3 and 5, but Is Better Tolerated

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only